Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Athira Pharma, Inc. (NASDAQ: ATHA) SEC filings page brings together the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Athira, which has announced a name change to LeonaBio, Inc. with a future ticker "LONA," uses filings such as Forms 8-K and 8-K/A to report material events related to its operations, capital structure and key licensing agreements.
Recent filings describe a 10-for-1 reverse stock split of common stock, implemented through a certificate of amendment in Delaware, and subsequent confirmation from The Nasdaq Stock Market that Athira regained compliance with the minimum bid price requirement. Other 8-K filings detail a private placement financing involving common stock, pre-funded warrants and accompanying common warrants, with gross proceeds expected to be approximately $90 million, and outline associated registration rights for investors.
Filings also cover Athira’s exclusive licensing arrangements for lasofoxifene with Sermonix Pharmaceuticals and Ligand Pharmaceuticals, including the assumption of responsibility for the global Phase 3 ELAINE-3 trial outside specified retained territories. These documents provide insight into how the company structures rights to develop, manufacture and commercialize oral forms of lasofoxifene and how it coordinates with partners.
On this page, users can review Athira’s current reports to understand how financing terms, warrant structures, reverse stock split mechanics and licensing obligations interact with its clinical programs in metastatic breast cancer and ALS. Stock Titan’s platform adds AI-powered summaries to help explain the key points of lengthy filings, highlight important dates and thresholds, and make it easier to interpret how each filing may relate to Athira/LeonaBio’s broader strategic and clinical plans.
LeonaBio, Inc. is registering 58,464,567 shares of common stock for resale by the selling stockholders, to be offered from time to time by the holders identified under “Principal and Selling Stockholders.” The company is not selling any shares hereunder and will receive no proceeds from secondary sales.
LeonaBio would receive cash proceeds only if selling holders exercise certain warrants: cash exercise of 8,816,684 pre-funded warrants at $0.001 would yield approximately $8,816, and cash exercise of up to 23,031,494 warrants at $6.35 would yield approximately $146,249,987. Sales are subject to the PIPE warrants’ exercise limitations and beneficial ownership caps described in the prospectus.
LeonaBio, Inc. registers 5,502,402 shares of common stock for resale by the selling stockholder—shares issuable upon exercise of a pre-funded warrant. The prospectus states the company will receive proceeds only if the pre-funded warrant is exercised for cash at $0.001 per share, which would yield approximately $5,502.
The pre-funded warrant was issued to Sermonix Pharmaceuticals, Inc. as partial consideration for a license agreement and is subject to a 4.99% beneficial ownership limit and other exercise restrictions; stockholder approval for issuance upon exercise was obtained on March 18, 2026.
LeonaBio, Inc. is registering up to 5,502,402 shares of common stock for resale by Sermonix Pharmaceuticals, Inc., issuable upon exercise of a pre-funded warrant from a December 2025 licensing transaction. LeonaBio will not sell any shares in this offering and receives no resale proceeds.
The company will receive only the nominal cash exercise price of $0.001 per share, or about $5,502 in gross proceeds if the warrant is fully exercised. As of March 16, 2026, LeonaBio had 9,393,514 shares of common stock outstanding, and its stock traded at $8.42 per share on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. is registering up to 58,464,567 shares of common stock for resale by existing investors under a Form S-1 converted from a prior Form S-3. These shares include stock already issued and shares issuable from pre-funded warrants and other warrants held by December 2025 private placement investors.
LeonaBio will not sell any shares in this offering and will not receive proceeds from selling stockholders’ resales. It may receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share, and approximately $146,249,987 from cash exercises of warrants on 23,031,494 underlying shares at $6.35 per share. As of March 16, 2026, 9,393,514 shares of common stock were outstanding, and the stock traded at $8.42 on Nasdaq under the symbol LONA.
LeonaBio, Inc. reports its business overview and drug pipeline, highlighting two main programs: lasofoxifene for ESR1‑mutated metastatic breast cancer and ATH‑1105 for amyotrophic lateral sclerosis (ALS). The company in‑licensed global rights (excluding Asia and parts of the Middle East) to oral lasofoxifene from Sermonix and Ligand and is assuming responsibility for the ongoing Phase 3 ELAINE‑3 trial, which combines lasofoxifene with abemaciclib. Earlier Phase 2 data showed median progression‑free survival of 5.6 months for lasofoxifene versus 3.7 months for fulvestrant, and 13‑month median progression‑free survival for lasofoxifene plus abemaciclib in heavily pretreated patients. ATH‑1105 is an oral small molecule that positively modulates the neurotrophic HGF/MET system, with extensive preclinical ALS data showing neuroprotection, reduced inflammation and improved motor function, and a completed Phase 1 trial in healthy volunteers demonstrating favorable safety, dose‑proportional pharmacokinetics and CNS penetration. LeonaBio outlines plans for a Phase 2 ALS trial focused on neurofilament light chain as a biomarker and describes broad intellectual property coverage and third‑party manufacturing arrangements to support potential commercialization.
LeonaBio, Inc. filed a second amendment to an earlier report to align with SEC guidance treating its Sermonix transaction as an acquisition of a business. The company obtained a waiver from certain financial statement requirements in exchange for providing expanded qualitative and cash expenditure disclosures.
The amendment details historical unaudited cash spending on the ELAINE-3 Study, including about $14 million, $12 million and $5 million by Sermonix in 2023, 2024 and part of 2025, and approximately $11 million by LeonaBio from December 18 through December 31, 2025. LeonaBio now expects to spend about $45 million in 2026 and $30 million in 2027 as it broadens the study scope.
The company has increased the ELAINE-3 Study intensity, expanded the contract research organization’s responsibilities, and plans to raise the sample size from 500 to up to 600 participants. It currently expects to complete enrollment in the fourth quarter of 2026 and release topline data in the second half of 2027.
LeonaBio, Inc. reported full-year 2025 results and highlighted a major strategic shift toward oncology and neurodegeneration. For the year ended December 31, 2025, cash, cash equivalents and investments rose to $88.3 million from $51.3 million, helped by a $90 million private placement of common stock and warrants that could bring in up to an additional $146 million if fully exercised.
Research and development expenses increased to $85.6 million, mainly from $68.1 million of acquired in‑process R&D tied to the lasofoxifene license, while general and administrative expenses fell to $16.7 million. Net loss widened modestly to $105.6 million, or $24.70 per share, compared with $96.9 million, or $25.19 per share, in 2024.
The company acquired an exclusive global license (excluding Asia and certain Middle East countries) to late‑stage breast cancer drug candidate lasofoxifene and is running the Phase 3 ELAINE‑3 trial, expecting enrollment completion in 4Q 2026 and topline data in 2H 2027. Its ALS candidate ATH‑1105 showed favorable Phase 1 safety and CNS penetration, with a Phase 2 proof‑of‑concept study in ALS planned to start in the second half of 2026.
LeonaBio, Inc. reported results of a special stockholder meeting where several major equity actions were approved. Stockholders adopted a new 2026 Equity Incentive Plan allowing issuance of up to 5,700,000 shares, plus up to 1,300,000 additional shares recycled from certain expired or forfeited awards under the prior 2020 plan, and an annual increase tied to up to 5% of outstanding common stock and pre-funded warrants.
Stockholders also approved potential issuances of common stock upon exercise of a Sermonix pre-funded warrant for 5,502,402 shares and additional warrant exercises by Perceptive Advisors that could raise their beneficial ownership above 19.99%, consistent with Nasdaq Rules 5635(a)(2) and 5635(b). In a major capital structure change, authorized common stock increased from 90,000,000 to 400,000,000 shares and total authorized capital stock from 190,000,000 to 500,000,000 shares via a certificate of amendment filed on March 18, 2026.